N.M. Admin. Code § 16.19.26.13 - HORMONAL CONTRACEPTION DRUG THERAPY
A.
Protocol:
(1) Prescriptive authority for hormonal
contraception drug therapy shall be exercised solely in accordance with the
written protocol for hormonal contraception drug therapy approved by the
board.
(2) Any pharmacist
exercising prescriptive authority for hormonal contraception drug therapy must
maintain a current copy of the written protocol for hormonal contraception drug
therapy approved by the board.
B.
Education and training:
(1) The pharmacist must successfully complete
a course of training, accredited by the accreditation council for pharmacy
education (ACPE), in the subject of hormonal contraception drug therapy
provided by:
(a) the New Mexico pharmacists
association or;
(b) a similar
health authority or professional body approved by the board.
(2) Training must include study
materials and instruction in the following content areas:
(a) mechanisms of action, contraindication,
drug interaction and monitoring of hormonal contraception drug
therapy;
(b) current standards for
prescribing hormonal contraception drug therapy;
(c) identifying indications for use of
hormonal contraception drug therapy;
(d) interviewing patient to establish need
for hormonal contraception drug therapy;
(e) counseling patient regarding the safety,
efficacy and potential adverse effects of drug products for hormonal
contraception;
(f) evaluating
patient's medical profile for drug interaction;
(g) referring patient follow-up care with
primary healthcare provider;
(h)
informed consent;
(i) management of
adverse events, including identification, appropriate response, documentation
and reporting.
(3)
Continuing education: any pharmacist exercising prescriptive authority for
hormonal contraception drug therapy shall complete a minimum of 0.2 CEU of live
ACPE approved hormonal contraception drug therapy related continuing education
every two years. Such continuing education shall be in addition to requirements
in 16.19.4.10 NMAC.
C.
Authorized drugs:
(1) Prescriptive authority shall be limited
to hormonal contraception drug therapy and shall exclude any device intended to
prevent pregnancy after intercourse.
(2) Prescriptive authority for hormonal
contraception drug therapy shall be limited to those drugs delineated in the
written protocol for hormonal contraception drug therapy approved by the
board.
D.
Records:
(1) The prescribing
pharmacist must generate a written or electronic prescription for any dangerous
drug authorized.
(2) Informed
consent must be documented in accordance with the approved protocol for
hormonal contraception drug therapy and a record of such consent maintained in
the pharmacy for a period of at least three years.
E.
Notification: Upon signed
consent of the patient or guardian, the pharmacist shall notify the patient's
designated physician or primary care provider of hormonal contraception drug
therapy prescribed.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.